"
Team:USTC CHINA/Project/AdvancingWork
From 2013.igem.org
(Difference between revisions)
| (24 intermediate revisions not shown) | |||
| Line 4: | Line 4: | ||
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" /> | <link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" /> | ||
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/pro.css?action=raw&ctype=text/css" /> | <link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/pro.css?action=raw&ctype=text/css" /> | ||
| + | |||
</head> | </head> | ||
<body background="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_Light_grey_bg.png"> | <body background="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_Light_grey_bg.png"> | ||
| Line 61: | Line 62: | ||
<div class="leftbar" align="left"> | <div class="leftbar" align="left"> | ||
<div class="basic-bar"> | <div class="basic-bar"> | ||
| - | < | + | <h2>Introduction<h2> |
| - | <p>According to our experiment result, we have proved the secretion and expression possibility of TD1-antigen, TD1-adjuvant, and the antigenicity of TD1-antigen after transdermal process. So in the following experiments, we decided to utilize B.subtilis WB800N as engineered bacteria, plus shuttle vector pHT43 as secretion vector to build the B.subtilis secretory expression system. On top of this, we have taken advantage of different kinds of TD1-antigen, testing HBsAg, PA, Ag85b that have been applied into the market to check the universal property of TD1-antigen. Besides, reporters essential during real application have been found to realize the final circuit.<p> | + | <p align="justify">According to our experiment result, we have proved the secretion and expression possibility of TD1-antigen, TD1-adjuvant, and the antigenicity of TD1-antigen after transdermal process. So in the following experiments, we decided to utilize <i>B.subtilis</i> WB800N as engineered bacteria, plus shuttle vector pHT43 as secretion vector to build the <i>B.subtilis</i> secretory expression system. On top of this, we have taken advantage of different kinds of TD1-antigen, testing HBsAg, PA, Ag85b that have been applied into the market to check the universal property of TD1-antigen. Besides, reporters essential during real application have been found to realize the final circuit.<p> |
<img src="https://static.igem.org/mediawiki/2013/c/cb/Further_work.png"width="580" height="250" /> | <img src="https://static.igem.org/mediawiki/2013/c/cb/Further_work.png"width="580" height="250" /> | ||
| + | <br></br> | ||
| + | <br></br> | ||
<div><h2>ONE: Expression of TD1-"X" in WB800N</h2></div> | <div><h2>ONE: Expression of TD1-"X" in WB800N</h2></div> | ||
<div><h3>1.Expression of TD1-GFP</h3></div> | <div><h3>1.Expression of TD1-GFP</h3></div> | ||
| Line 71: | Line 74: | ||
<div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig4. fluorescent microscope shows the expression of GFP in WB800N</div> | <div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig4. fluorescent microscope shows the expression of GFP in WB800N</div> | ||
<div><h3>2.Expression of TD1-antigen/adjuvant</h3></div> | <div><h3>2.Expression of TD1-antigen/adjuvant</h3></div> | ||
| - | + | <p align="justify">In order to realize the secretory expression in <i>B.subtilis</i>, we inserted signal peptide between promoter and the TD1-Antigen/adjuvant sequence to secrete our recombinant protein. GFP was chosen to check the reliability of this circuit. After large amounts of experiments, GFP has finally been found via fluorescence microscope.</p> | |
<img src="https://static.igem.org/mediawiki/2013/f/f0/Pctc-sp-td1-antigenadjuvent.png"width="580" height="120" /> | <img src="https://static.igem.org/mediawiki/2013/f/f0/Pctc-sp-td1-antigenadjuvent.png"width="580" height="120" /> | ||
| - | <div><p>Then, three kinds of recombinant antigen, TD1-HBsAg, TD1-PA, TD1-Ag85b, and recombinant immunologic adjuvant were designed. The earliest successful protein TD1-LTB can not only be observed clear stripes in SDS-PAGE, but also be proved according to HPLC-MS.</p></div> | + | <div><p align="justify">Then, three kinds of recombinant antigen, TD1-HBsAg, TD1-PA, TD1-Ag85b, and recombinant immunologic adjuvant were designed. The earliest successful protein TD1-LTB can not only be observed clear stripes in SDS-PAGE, but also be proved according to HPLC-MS.</p></div> |
<img src="https://static.igem.org/mediawiki/igem.org/f/fd/20-%E6%9E%AF%E8%8D%89%E8%9B%8B%E7%99%BD%E8%A1%A8%E8%BE%BE.jpg" width="580" height="300"> | <img src="https://static.igem.org/mediawiki/igem.org/f/fd/20-%E6%9E%AF%E8%8D%89%E8%9B%8B%E7%99%BD%E8%A1%A8%E8%BE%BE.jpg" width="580" height="300"> | ||
<div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig5. SDS PAGE shows the expression of LTB in WB800N</div> | <div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig5. SDS PAGE shows the expression of LTB in WB800N</div> | ||
| + | <br></br> | ||
| + | <br></br> | ||
<div><h2>TWO: Neomycin resistance of WB800N</h2></div> | <div><h2>TWO: Neomycin resistance of WB800N</h2></div> | ||
| - | <div><h3>Selection on the of resistance of B.subtilis WB800N against neomycin</h3> | + | <div><h3>Selection on the of resistance of <i>B.subtilis</i> WB800N against neomycin</h3> |
| - | <p>As WB800N is a novel secretory expression system, most of whose parameters remain unclear, among which the chief problem is that its unique resistance against neomycin has never been quantitatively analyzed, and our work made up for this blank.</p></div> | + | <p align="justify">As WB800N is a novel secretory expression system, most of whose parameters remain unclear, among which the chief problem is that its unique resistance against neomycin has never been quantitatively analyzed, and our work made up for this blank.</p></div> |
<img src="https://static.igem.org/mediawiki/2013/f/f7/Xinmeisu.png" width="580" height="300"> | <img src="https://static.igem.org/mediawiki/2013/f/f7/Xinmeisu.png" width="580" height="300"> | ||
| - | <div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig6. Selection on the of resistance of B.subtilis WB800N against neomycin</div> | + | <div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig6. Selection on the of resistance of <i>B.subtilis</i> WB800N against neomycin</div> |
| - | <div><p>We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.</p></div> | + | <div><p align="justify">We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.</p></div> |
| + | <br></br> | ||
| + | <h2>THREE: Mice Experiment is in Progress</h2> | ||
| + | <h3>Specific Pathogen Free (SPF) Laboratory</h3> | ||
| + | <div><p align="justify">Specific Pathogen Free is a term used for laboratory animals that are guaranteed free of particular pathogens. Use of SPF animals ensures that specified diseases do not interfere with an experiment. For example, absence of respiratory pathogens such as influenza is desirable when investigating a drug's effect on lung function.</p></div> | ||
| + | <div align="center"> | ||
| + | <img src="https://static.igem.org/mediawiki/2013/2/22/DSC_0106.jpg"></br></br> | ||
| + | <div class="atfigure" align="center" style="width:580px; font-size:14px">Fig7. This is where we conducted mice experiments,Specefic pathogen Free(SPF) Experiment Center</div> | ||
| + | <img src="https://static.igem.org/mediawiki/2013/3/36/DSC_0099.jpg"></br></br> | ||
| + | <div class="atfigure" align="center" style="width:580px; font-size:14px">Fig8. Our lab-gown</div> | ||
| + | <h3 align="left">Mice Experiment</h3> | ||
| + | <p align="justify">This year our team achieved a remarkable breakthrough in the history of iGEM by not only fulfilling molecular biology experiments but also trying animal experiments. To verify that our T-Vaccine possesses immunogenicity and is able to trigger valid immune memory in mice like traditional vaccines, we started advancing work in SPF laboratory of our university. As mice experiments are costly and time-consuming, our further results will be announced soon. We also hope T-Vaccine will be available for every family to realize our final dream: A World without Needles!</p><br></br> | ||
| + | <img src="https://static.igem.org/mediawiki/2013/0/02/DSC_0088.jpg"></br></br> | ||
| + | <div class="atfigure" align="center" style="width:580px; font-size:14px">Fig9. We were observing mice</div> | ||
| + | <img src="https://static.igem.org/mediawiki/2013/0/02/DSC_0109.jpg"></br></br> | ||
| + | <div class="atfigure" align="center" style="width:580px; font-size:14px">Fig10. Mice for our experiments</div> | ||
</div> | </div> | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
<div style="float:right;font-size:26px;margin:20px auto 20px 0;"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/FutureWork">Future Work >>></a></div> | <div style="float:right;font-size:26px;margin:20px auto 20px 0;"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/FutureWork">Future Work >>></a></div> | ||
| + | </div> | ||
</div> | </div> | ||
<div class="rightbar"> | <div class="rightbar"> | ||
| Line 98: | Line 112: | ||
<div class="clear"></div> | <div class="clear"></div> | ||
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div> | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div> | ||
| - | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project | + | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Background">Background</a></div> |
| - | + | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">Design</a></div> | |
| - | <div id=" | + | |
<div id="t1"><a class="active" href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div> | <div id="t1"><a class="active" href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div> | ||
| - | <div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Basic Experiment</a></div> | + | <div id="t2"><a class="active" href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Basic Experiment</a></div> |
| - | <div id="t2"><a | + | <div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/AdvancingWork">Advancing Work</a></div> |
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/FutureWork">Future Work</a></div> | <div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/FutureWork">Future Work</a></div> | ||
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></div> | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></div> | ||
| - | |||
</div></div></div> | </div></div></div> | ||
Latest revision as of 12:35, 28 October 2013
Introduction
According to our experiment result, we have proved the secretion and expression possibility of TD1-antigen, TD1-adjuvant, and the antigenicity of TD1-antigen after transdermal process. So in the following experiments, we decided to utilize B.subtilis WB800N as engineered bacteria, plus shuttle vector pHT43 as secretion vector to build the B.subtilis secretory expression system. On top of this, we have taken advantage of different kinds of TD1-antigen, testing HBsAg, PA, Ag85b that have been applied into the market to check the universal property of TD1-antigen. Besides, reporters essential during real application have been found to realize the final circuit.
ONE: Expression of TD1-"X" in WB800N
1.Expression of TD1-GFP
Fig4. fluorescent microscope shows the expression of GFP in WB800N
2.Expression of TD1-antigen/adjuvant
In order to realize the secretory expression in B.subtilis, we inserted signal peptide between promoter and the TD1-Antigen/adjuvant sequence to secrete our recombinant protein. GFP was chosen to check the reliability of this circuit. After large amounts of experiments, GFP has finally been found via fluorescence microscope.
Then, three kinds of recombinant antigen, TD1-HBsAg, TD1-PA, TD1-Ag85b, and recombinant immunologic adjuvant were designed. The earliest successful protein TD1-LTB can not only be observed clear stripes in SDS-PAGE, but also be proved according to HPLC-MS.
Fig5. SDS PAGE shows the expression of LTB in WB800N
TWO: Neomycin resistance of WB800N
Selection on the of resistance of B.subtilis WB800N against neomycin
As WB800N is a novel secretory expression system, most of whose parameters remain unclear, among which the chief problem is that its unique resistance against neomycin has never been quantitatively analyzed, and our work made up for this blank.
Fig6. Selection on the of resistance of B.subtilis WB800N against neomycin
We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.
THREE: Mice Experiment is in Progress
Specific Pathogen Free (SPF) Laboratory
Specific Pathogen Free is a term used for laboratory animals that are guaranteed free of particular pathogens. Use of SPF animals ensures that specified diseases do not interfere with an experiment. For example, absence of respiratory pathogens such as influenza is desirable when investigating a drug's effect on lung function.
Fig7. This is where we conducted mice experiments,Specefic pathogen Free(SPF) Experiment Center
Fig8. Our lab-gown
Mice Experiment
This year our team achieved a remarkable breakthrough in the history of iGEM by not only fulfilling molecular biology experiments but also trying animal experiments. To verify that our T-Vaccine possesses immunogenicity and is able to trigger valid immune memory in mice like traditional vaccines, we started advancing work in SPF laboratory of our university. As mice experiments are costly and time-consuming, our further results will be announced soon. We also hope T-Vaccine will be available for every family to realize our final dream: A World without Needles!
Fig9. We were observing mice
Fig10. Mice for our experiments
